CO6270365A2 - Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprende - Google Patents
Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprendeInfo
- Publication number
- CO6270365A2 CO6270365A2 CO10057470A CO10057470A CO6270365A2 CO 6270365 A2 CO6270365 A2 CO 6270365A2 CO 10057470 A CO10057470 A CO 10057470A CO 10057470 A CO10057470 A CO 10057470A CO 6270365 A2 CO6270365 A2 CO 6270365A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- heterociclical
- derivative
- composition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invencion se relaciona con un derivado heterociclico de acuerdo con la formula (I) en donde las variables se definen como en la especificacion, o con una sal farmacéuticamente aceptable o solvato del mismo. La presente invencion también se relaciona con una composicion farmacéutica que comprende dichos derivados heterociclicos y con su uso en terapia, por ejemplo en el tratamiento o prevencion de enfermedades siquiatricas donde se requiera una mejora de las respuestas sinapticas mediadas por los receptores AMPA, que incluyen esquizofrenia, depresion y trastornos de aprendizaje y memoria tales como enfermedad de Alzheimer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07120603 | 2007-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6270365A2 true CO6270365A2 (es) | 2011-04-20 |
Family
ID=39472607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10057470A CO6270365A2 (es) | 2007-11-13 | 2010-05-13 | Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprende |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8129397B2 (es) |
| EP (1) | EP2209791B1 (es) |
| JP (1) | JP5455130B2 (es) |
| KR (1) | KR20100106370A (es) |
| CN (1) | CN101855227B (es) |
| AR (1) | AR069286A1 (es) |
| AU (1) | AU2008322986B2 (es) |
| BR (1) | BRPI0819202A2 (es) |
| CA (1) | CA2703901C (es) |
| CL (1) | CL2008003362A1 (es) |
| CO (1) | CO6270365A2 (es) |
| EC (1) | ECSP10010247A (es) |
| MX (1) | MX2010004686A (es) |
| PE (1) | PE20091167A1 (es) |
| RU (1) | RU2010123895A (es) |
| TW (1) | TW200934497A (es) |
| WO (1) | WO2009062930A1 (es) |
| ZA (1) | ZA201002580B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| US20170313719A1 (en) * | 2014-11-18 | 2017-11-02 | Emory University | Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto |
| PT3386591T (pt) | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
| EP4219507A3 (en) | 2015-12-09 | 2023-08-16 | Novartis AG | Thienopyrimidinone nmda receptor modulators and uses thereof |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| GB201702221D0 (en) * | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| KR20210039432A (ko) | 2018-08-03 | 2021-04-09 | 카덴트 테라퓨틱스, 인크. | 헤테로방향족 nmda 수용체 조절제 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2541458C (en) * | 2003-10-08 | 2011-09-20 | Eli Lilly And Company | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors |
| ATE552251T1 (de) * | 2004-01-09 | 2012-04-15 | Lilly Co Eli | Thiophen- und furanverbindungen |
| AU2006227729B2 (en) * | 2005-03-16 | 2011-10-13 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
| GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| AU2006258461B2 (en) * | 2005-06-14 | 2011-08-25 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine derivative |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
-
2008
- 2008-10-28 TW TW097141383A patent/TW200934497A/zh unknown
- 2008-11-11 KR KR1020107012728A patent/KR20100106370A/ko not_active Application Discontinuation
- 2008-11-11 RU RU2010123895/04A patent/RU2010123895A/ru unknown
- 2008-11-11 WO PCT/EP2008/065306 patent/WO2009062930A1/en active Application Filing
- 2008-11-11 CN CN2008801156861A patent/CN101855227B/zh active Active
- 2008-11-11 CA CA2703901A patent/CA2703901C/en active Active
- 2008-11-11 EP EP08849917.3A patent/EP2209791B1/en active Active
- 2008-11-11 BR BRPI0819202 patent/BRPI0819202A2/pt not_active IP Right Cessation
- 2008-11-11 MX MX2010004686A patent/MX2010004686A/es not_active Application Discontinuation
- 2008-11-11 AU AU2008322986A patent/AU2008322986B2/en active Active
- 2008-11-11 JP JP2010533556A patent/JP5455130B2/ja active Active
- 2008-11-12 AR ARP080104926A patent/AR069286A1/es unknown
- 2008-11-12 US US12/269,306 patent/US8129397B2/en active Active
- 2008-11-12 CL CL2008003362A patent/CL2008003362A1/es unknown
- 2008-11-12 PE PE2008001915A patent/PE20091167A1/es not_active Application Discontinuation
-
2010
- 2010-04-13 ZA ZA2010/02580A patent/ZA201002580B/en unknown
- 2010-05-13 CO CO10057470A patent/CO6270365A2/es not_active Application Discontinuation
- 2010-06-11 EC EC2010010247A patent/ECSP10010247A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008322986B2 (en) | 2013-08-01 |
| CN101855227B (zh) | 2013-01-23 |
| CA2703901A1 (en) | 2009-05-22 |
| AU2008322986A1 (en) | 2009-05-22 |
| CA2703901C (en) | 2016-05-10 |
| KR20100106370A (ko) | 2010-10-01 |
| CL2008003362A1 (es) | 2009-06-26 |
| RU2010123895A (ru) | 2011-12-20 |
| CN101855227A (zh) | 2010-10-06 |
| ZA201002580B (en) | 2010-12-29 |
| AR069286A1 (es) | 2010-01-13 |
| US8129397B2 (en) | 2012-03-06 |
| EP2209791A1 (en) | 2010-07-28 |
| ECSP10010247A (es) | 2010-07-30 |
| JP2011503139A (ja) | 2011-01-27 |
| TW200934497A (en) | 2009-08-16 |
| MX2010004686A (es) | 2010-05-19 |
| PE20091167A1 (es) | 2009-08-03 |
| BRPI0819202A2 (pt) | 2015-05-05 |
| EP2209791B1 (en) | 2014-01-22 |
| US20090131455A1 (en) | 2009-05-21 |
| JP5455130B2 (ja) | 2014-03-26 |
| WO2009062930A1 (en) | 2009-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6270365A2 (es) | Derivado heterociclico con una sal farmaceuticamente aceptable o solvato del mismo y composicion que lo comprende | |
| NI200900204A (es) | COMPUESTOS AMINO-HETEROCÍCLICOS. Caso: PC 33468A | |
| DOP2011000135A (es) | Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
| BR112012008518A2 (pt) | derivado heterocíclico, e, composição farmacêutica | |
| PA8627201A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| CO6501188A2 (es) | Moduladores de piranil aril metil benzoquinazolina alostéricos positivos del receptos m1 | |
| GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
| BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| UY30426A1 (es) | Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones. | |
| AR077252A1 (es) | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos | |
| DOP2006000169A (es) | Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ECSP12011622A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
| ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
| ECSP077424A (es) | Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3 | |
| BRPI0416989A (pt) | derivados aminopirazole como inibidores gsk-3 | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| CR20120289A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
| BRPI0514735A (pt) | derivados de piridino sulfonamida como moduladores do receptor de quimiocina | |
| BR0315158A (pt) | Compostos de pirazol para o tratamento de distúrbios neurodegenarativos | |
| UY30835A1 (es) | 8-alquinilxantinas y derivados | |
| CO2021002976A2 (es) | Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak | |
| CR10387A (es) | Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor | |
| AR061792A1 (es) | Derivados heterociclicos y su uso en el tratamiento o prevencion de enfermedades psiquiatricas donde se requiere un aumento de las respuestas sinapticas mediadas por receptores ampa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |